ERBB2 and breast carcinoma: Invasive disease‐free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor‐positive, HER2‐negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial